Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Epilepsy Therapeutics Market Analysis and Forecast, 2015 to 2021

Zion Market Research
Posted on: 19 Aug 16

Epilepsy is a chronic neurological disorder characterized by unpredictable seizures. Epilepsy is the fourth most common neurological disorder that affects peoples of all age group. Seizures may be classified as focal seizures, generalized seizures, and other seizures. Focal seizures are the most common type of epilepsy which involves secondary generalized tonic/clonic seizures (sGTCS) and complex partial seizures. Generalized seizures include myoclonic seizures, tonic seizures, atonic seizures, absences, and clonic seizures. These seizures occur when neurons in the brain or a group of nerve cells send wrong signals to the body.

Request Sample Report:

Treatment of epilepsies is done by using antiepileptic drugs (AEDs). Antiepileptic drugs are segmented into two major categories namely first generation AEDs and second generation AEDs. Selection of drugs is done by prescriber depending upon the type of seizure, part of brain involved in epilepsy, age of patient.

Epilepsy therapeutic drug market is mostly driven by increasing prevalence of neurological disorders and technological advancements across many countries. Moreover, increasing awareness about diagnostics and treatment of neurological disorders in global market also help in driving the epileptic market growth. Non availability of medical facilities in poor and developing countries can restrict or hinder the growth of epileptic therapeutic market over the years. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market. Nonetheless, ongoing research and development in the healthcare literacy rate are expected to open growth avenues for the market over the years.

Request TOC (Table of Contents) of this report:

The report covers forecast and analysis of the epileptic therapeutic market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million).  To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the epileptic therapeutic drug market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein type segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides detailed segmentation of the epileptic therapeutic drug market based on type and regional segment.

Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Demand has been analyzed and forecast based on the current trends for the period of six years. North America & Europe were the leading regional segments of the epileptic therapeutic drug market due to availability of second generation antiepileptic drug.

Three new AEDs have been approved in the U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Ezogabine/retigabine and perampanel among these have new mechanism of action and thus it is capturing good amount of market share in the U.S. The epileptic therapeutic market is expected to witness the highest growth in the Asia-Pacific region in the coming years due to high prevalence of epilepsy in India and China, increasing health care infrastructure, incomes and awareness.

Browse report at:

Key players in epileptic therapeutic market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.

This report segments the epileptic therapeutic market are:-

Epileptic Therapeutic Market: Type Segment Analysis

  • First Generation
  • Second Generation

Epileptic Therapeutic Market: Regional Segment Analysis

  • North America
  • Europe
  • Asia pacific
  • Latin America
  • Middle east & Africa

Do Inquiry before buying:

About Us:
Zion Market Research is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Zion Market Research is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading industry and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:
Zion Market Research
4283, Express Lane,
Suite 634-143,
Sarasota, Florida 34249, United States 
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

For more information:

Editor's Details

Allan Leonetti
Zion Market Research

Last updated on: 19/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.